Given that over 90% of patients with gastric metastases are estrogen receptor positive, we propose that a systemic therapy approach combined with hormone therapy represents the optimal treatment strategy for breast cancer patients with gastric metastases. This evidence concerns the gene ESR1 and breast cancer.